Hemoglobin >= 10.0 g/dL and no blood transfusions in the 28 days prior to entry/randomization
Hemoglobin >= 8 g/dL (blood transfusions are permitted for patients with hemoglobin levels below 8 g/dL) (within 14 days of treatment initiation)
Procurement: Hemoglobin (Hgb) > 8.0 g/dl (transfusions allowed)
Hemoglobin levels at the time of or within 7 days prior to transfusions must have been ? 9.0 g/dL for the transfusions to qualify as required for the purpose of providing evidence of transfusion-dependent anemia.
Hemoglobin (Hgb) >= 10 g/dL (may be achieved with erythropoietin agents; no blood transfusions in the 28 days prior to entry)
PROCUREMENT: Hemoglobin (Hgb) > 8.0 (transfusions allowed)
TREATMENT: Hgb > 8.0 g/dL (transfusions allowed)
Hemoglobin >= 9.0 gm/dL (may receive RBC transfusions)
Hemoglobin >= 8 g/dL\r\n* Note: Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must not begin earlier
Hemoglobin >= 9 g/dL performed within 30 days prior to the date of registration; no transfusions and erythropoietin supplementation permitted within the last 3 months
Hemoglobin greater than 9.0 mg/dl (transfusions are permitted to achieve baseline hemoglobin level), within 14 days prior to registration
Hemoglobin >= 8.0 g/dL (may receive transfusions)
Hemoglobin >= 8 g/dl (may receive transfusions)
INCLUSION CRITERIA FOR STRATUM C: Hemoglobin >= 8 g/dl (may receive transfusions)
Hemoglobin >= 8 g/dL (transfusions are permissible)
Hemoglobin >= 9 g/dL (transfusions allowed)
Hemoglobin >= 9 g/dL, with no blood transfusions in the 28 days prior to study entry
Hemoglobin >= 9 g/dL (transfusions permitted)
Within 14 days prior to registration: Hemoglobin >= 8.0 mg/dl (transfusions are permitted to achieve baseline hemoglobin level)
Hemoglobin >= 8 g/dL; RBC transfusions and use of G-CSF will be allowed in order to meet eligibility parameters (unless dysfunction is secondary to lymphoma involvement)
Hemoglobin ? 8.0 g/dL (may receive transfusions)
Hemoglobin ? 9 g/dL (transfusions are allowed)
Hemoglobin >= 9 g/dl (no blood transfusions within 4 weeks prior to enrollment)
hemoglobin ? 9.0 g/dL (transfusions permissible)
Hemoglobin (Hgb) >= 9 g/dL without transfusions
CAPMATINIB INCLUSION CRITERIA: Hemoglobin >= 9 g/dL (transfusions are allowed)
CERITINIB INCLUSION CRITERIA: Hemoglobin >= 8 g/dL (transfusions are allowed)
ENTRECTINIB INCLUSION CRITERIA: Hemoglobin >= 8 g/dL (transfusions are allowed)
Hemoglobin > 8g/dL (may receive transfusions).
Hemoglobin (Hgb) >= 9 g/dL (transfusions allowed)
Hemoglobin >= 9.0 g/dL and no blood transfusions in the 28 days prior to enrollment
INCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: Hemoglobin >= 9.0 g/dL (transfusions are permitted)
PROCUREMENT: Hemoglobin (Hgb) > 8.0 (transfusions allowed)
Hemoglobin >= 8 g/dl (may receive transfusions)
Hemoglobin (Hgb) ? 9 g/dL. NOTE: subject must not have received any growth factor or blood transfusions within 14 days prior to the hematology values obtained at screening. Subjects requiring transfusions to meet eligibility criteria are not eligible.
Hemoglobin at least 8.0 grams per deciliter (g/dL) at Baseline (blood transfusions are allowed during the screening period to correct hemoglobin values less than 8.0 g/dL) As blood transfusions are permitted to meet the hemoglobin criteria, participants requiring transfusion must not be known to be refractory to red blood cell or platelet transfusions.
Hemoglobin (Hgb) >= 9 g/dL without transfusions
Hemoglobin >= 8 g/dL (may receive transfusions)
To be performed within 28 days prior to day 1 of protocol therapy: Hemoglobin (Hgb) >= 8 g/dL without transfusions
Hemoglobin >= 10 g/dL (transfuse as necessary to raise levels, no transfusions within 7 days of start)
Hemoglobin greater than 8 g/dl (patients may receive transfusions to meet this parameter)
Hemoglobin (Hgb) >= 9.0 g/dL (transfusions allowed)
Hemoglobin >= 9 g/dL\r\n* Blood transfusions are allowed at any time during the screening, treatment or follow-up period, according to the center recommendations
Hemoglobin >= 90 g/L\r\n* Blood transfusions are allowed at any time during the screening, treatment or follow-up period, according to the center recommendations
Hemoglobin >= 9 g/dL (prior to transfusions)
Hemoglobin >= 9 g/dL (transfusions are acceptable)
Hemoglobin >= 10 g/dL (transfusions are not permissible)
Hemoglobin >= 8 g/dL (may receive transfusions)
Hemoglobin >= 9 g/dL (transfusions allowed)
Hemoglobin >= 9.0 g/dL (not requiring transfusions within the past 2 weeks)
Hemoglobin >= 8 g/dL\r\n* Transfusions and erythropoietin supplementation permitted
Hemoglobin (Hgb) greater than or equal to 9 g/dL (transfusions are allowed)
Hemoglobin value >= 9 g/dL (Note: patients whose anemia has been corrected to a hemoglobin value >= 9 g/dL with blood transfusions are allowed)
Hemoglobin value >= 9 g/dL (Note: patients whose anemia has been corrected to a hemoglobin value >= 9 g/dL with blood transfusions are allowed)
Hemoglobin >= 9.0 g/dL not requiring transfusions within the past 2 weeks
Hemoglobin: >= 8 g/dL (no transfusions within 7 days) within 30 days prior to registration
Within 8 weeks of randomization: Hemoglobin value >= 9 g/dL (Note: patients whose anemia has been corrected to a hemoglobin value >= 9 g/dL with blood transfusions are allowed)
Hemoglobin (Hgb) >= 9 g/dL without transfusions
Participants requiring blood transfusions to maintain hemoglobin (Hgb) eligibility
TREATMENT: Hemoglobin greater than 8 g/dl (patients may receive transfusions to meet this parameter)
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Hemoglobin >= 8 g/dl (may receive transfusions)
NON-PROGRESSED DIPG (STRATUM 2): Hemoglobin >= 8 g/dl (may receive transfusions)
Hemoglobin >= 8 g/dL (transfusions are permissible)
Hemoglobin ? 9 g/dL (with no RBC transfusions within 7 days of Screening)
Hemoglobin >= 8.0 g/dL (may receive transfusions)
Hemoglobin >= 5.59 mmol/L or 9 g/dL; up to 5% deviation is tolerated; transfusions and growth factors are allowed
Hemoglobin (Hgb) >= 9 g/dL without transfusions
Hematologic: Absolute neutrophil count > 1.5 x 109/L, platelets > 100 x 109/L, hemoglobin ? 9 g/dL (Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. The first dose of study drug must not begin until 5 days after the erythrocyte transfusion);
Hemoglobin >= 9.0 g/dL (not requiring transfusions within the past 2 weeks)
Hemoglobin (Hb) >= 9g/dL (women) or >= 11g/dL (men) (supportive transfusions will be allowed during induction and maintenance phases to maintain these levels)
Hemoglobin >= 8 g/dL (with transfusions)
Hemoglobin ? 9 g/dL (transfusions are allowed)
Hemoglobin >= 9.0 g/dL not requiring transfusions within the past 2 weeks
Hemoglobin > 10 g/dL (transfusions allowed)
Hemoglobin greater than 8g/dl (patients may receive transfusions to meet this parameter)
Hemoglobin (Hgb) >= 9 g/dL without transfusions
Hemoglobin > 8 g/dL (international system [SI] units: 80 g/L); patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must not begin earlier than the day after the erythrocyte transfusion
Hemoglobin > 8 mg/dl; Physician can maintain a patient's hemoglobin with the use of erythropoietin or transfusions (prophylactic use of G-CSF [filgrastim] is not permitted)
Hemoglobin >= 9 g/dL (transfusions and/or erythropoietin are permitted)
Hemoglobin ?9 g/dL (?90 g/L) Note that transfusions are allowed to meet the required hemoglobin level
